MedTrace Logo

Neurofilament Light Chain And Voice Acoustic Analyses In Dementia Diagnosis

NCT06339190 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2025-05-30

No results posted yet for this study

Summary

This cohort study aims to determine if a blood test can aid with diagnosing dementia in anyone presenting with cognitive complaints to a single healthcare network. The investigators will measure levels of a brain protein, Neurofilament light chain (Nfl), and assess changes in language using speech tests.

Participants will have a single blood test and speech test, and will be followed up at 12-months to complete questionnaires and cognitive scales over the phone. The speech test will also be completed again at 12-months.

Individuals at risk of a Fronto-temporal dementia syndrome will be eligible to complete optional genetic testing involving an 'at home' saliva sample.

Conditions

Interventions

DIAGNOSTIC_TEST

Venepuncture

A single blood draw at the time of presentation to clinic or whilst an inpatient.

Sponsors & Collaborators

  • Eastern Health

    collaborator OTHER

  • University of Melbourne

    collaborator OTHER

  • Wake Forest University

    collaborator OTHER

  • Deakin University

    collaborator OTHER

  • The Florey Institute of Neuroscience and Mental Health

    collaborator OTHER

  • Invitae Corporation

    collaborator INDUSTRY

  • Redenlab

    collaborator UNKNOWN

  • Monash University

    lead OTHER

Principal Investigators

  • Prof. Amy Brodtmann, MBBS, FRACP, PhD, FANZAN · Monash University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-01
Primary Completion
2025-12-31
Completion
2027-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06339190 on ClinicalTrials.gov